

1 **Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac**
2 **vaccine recipients**

3
4 Lu Lu^{1*}, Bobo Wing-Yee Mok^{1*}, Linlei Chen^{1*}, Jacky Man-Chun Chan², Owen Tak-Yin Tsang²,
5 Bosco Hoi-Shiu Lam³, Vivien Wai-Man Chuang⁴, Allen Wing-Ho Chu¹, Wan-Mui Chan¹,
6 Jonathan Daniel Ip¹, Brian Pui-Chun Chan¹, Ruiqi Zhang⁵, Cyril Chik-Yan Yip^{1,6}, Vincent Chi-
7 Chung Cheng^{1,6}, Kwok-Hung Chan¹, Ivan Fan-Ngai Hung⁵, Kwok-Yung Yuen^{1,6}, Honglin
8 Chen¹, Kelvin Kai-Wang To^{1,6}

9
10 ¹State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection,
11 Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong,
12 Pokfulam, Hong Kong Special Administrative Region, People's Republic of China

13 ²Department of Medicine and Geriatrics, Princess Margaret Hospital, Hong Kong Special
14 Administrative Region, People's Republic of China

15 ³Department of Pathology, Princess Margaret Hospital, Hong Kong Special Administrative
16 Region, People's Republic of China

17 ⁴Quality & Safety Division, Hospital Authority, Hong Kong Special Administrative Region,
18 China.

19 ⁵Department of Medicine, Queen Mary Hospital, Hong Kong Special Administrative Region,
20 People's Republic of China

21 ⁶Department of Microbiology, Queen Mary Hospital, Hong Kong Special Administrative
22 Region, People's Republic of China

23

24 * These authors contribute equally

25 # **Corresponding authors:**

26 Kelvin Kai-Wang To

27 Email: kelvinto@hku.hk

28 Phone number: (852)-22552413

29 Carol Yu Centre for Infection, State Key Laboratory of Emerging Infectious Diseases,

30 Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong

31 Kong, Queen Mary Hospital, Pokfulam, Hong Kong, China

32

33 Kwok-Yung Yuen

34 Email: kyyuen@hku.hk

35 Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong

36 Kong, Queen Mary Hospital, Pokfulam, Hong Kong, China

37

38 **Word count:** Abstract: 250; Main text: 1772.

39 **Keywords:** SARS-CoV-2; Variant of Concern; Omicron variant; COVID-19 vaccine;

40 Neutralizing antibody

41 **Running title:** Omicron variant susceptibility

42

43

44

45 **ABSTRACT**

46 **Background**

47 The SARS-CoV-2 Omicron variant, designated as a Variant of Concern(VOC) by the
48 World Health Organization, carries numerous spike protein mutations which have been found to
49 evade neutralizing antibodies elicited by COVID-19 vaccines. The susceptibility of Omicron
50 variant by vaccine-induced neutralizing antibodies are urgently needed for risk assessment.

51 **Methods**

52 Omicron variant strains HKU691 and HKU344-R346K were isolated from patients using
53 TMPRSS2-overexpressing VeroE6 cells. Whole genome sequence was determined using
54 nanopore sequencing. Neutralization susceptibility of ancestral lineage A virus and the Omicron,
55 Delta and Beta variants to sera from 25 BNT162b2 and 25 Coronavac vaccine recipients was
56 determined using a live virus microneutralization assay.

57 **Results**

58 The Omicron variant strain HKU344-R346K has an additional spike R346K mutation,
59 which is present in 8.5% of strains in GISAID database. Only 20% and 24% of BNT162b2
60 recipients had detectable neutralizing antibody against the Omicron variant HKU691 and
61 HKU344-R346K, respectively, while none of the Coronavac recipients had detectable
62 neutralizing antibody titer against either Omicron isolates. For BNT162b2 recipients, the
63 geometric mean neutralization antibody titers(GMT) of the Omicron variant isolates(5.43 and
64 6.42) were 35.7-39.9-fold lower than that of the ancestral virus(229.4), and the GMT of both
65 omicron isolates were significantly lower than those of the beta and delta variants. There was no
66 significant difference in the GMT between HKU691 and HKU344-R346K.

67 **Conclusions**

68 Omicron variant escapes neutralizing antibodies elicited by BNT162b2 or CoronaVac.
69 The additional R346K mutation did not affect the neutralization susceptibility. Our data suggest
70 that the Omicron variant may be associated with lower COVID-19 vaccine effectiveness.

71 **INTRODUCTION**

72 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmits efficiently
73 among the human population [1]. Airborne transmission of SARS-CoV-2 within hospitals have
74 been reported [2]. Stringent public health and social measures have been implemented
75 worldwide in an effort to control the Coronavirus Disease 2019 (COVID-19) pandemic [3].

76 The availability of COVID-19 vaccine since late 2020 has offered hope that the pandemic
77 can be brought under control. At the time of writing, 8 COVID-19 vaccines have been validated
78 for use by the WHO under the Emergency Use Listing, including the inactivated whole-virion
79 vaccine (Coronavac, BBIBP-CorV, and Covaxin), mRNA vaccine (BNT162b2 and mRNA-
80 1273), and adenovirus-vector vaccine (Ad26.COV2.S, AZD1222, Covishield) [4]. However,
81 several variants with mutations in the spike protein receptor binding domain (RBD), especially at
82 the receptor binding motif (RBM), have emerged and have been found to escape neutralization
83 from antibodies in patients recovered from COVID-19 infection or vaccine recipients [5,6].
84 These variants, especially the Beta, Gamma and Delta variants, have been associated with
85 reduced vaccine effectiveness [7].

86 On 24th November 2021, South Africa and Botswana have alerted the World Health
87 Organization of a novel variant B.1.1.529, which has over 50 amino acid mutations, deletions or
88 insertions when compared with the ancestral virus strains first detected in December 2019. On
89 26th November, 2021, the World Health Organization has classified B.1.1.529 as a Variant of
90 Concern (VOC), and has named it the Omicron variant. The B.1.1.529 lineage has been
91 subsequently subdivided into BA.1 and BA.2. The Omicron variant appears to have transmitted
92 via the airborne route between two travelers who were quarantined at a hotel in Hong Kong [8].
93 Preliminary data from South Africa suggest that the emergence of Omicron variant is associated

94 with a higher risk of reinfection [9] and a faster doubling time [10]. Preliminary findings from
95 the United Kingdom suggest that the Omicron variant is associated with a higher risk of
96 transmission among household contacts than that of the Delta variant [11].

97 Because of the large number of mutations, especially at the spike RBD, there is a concern
98 that the Omicron variant can escape antibody neutralization induced by the current generation
99 COVID-19 vaccines. Here, we determined the neutralization susceptibility of two Omicron
100 variant isolates to antibodies from COVID-19 vaccine recipients, and compared with the
101 ancestral SARS-CoV-2 lineage A virus, the Beta variant, and the Delta variant.

102

103 **METHODS**

104 **Patients**

105 The virus strains hCoV-19/Hong Kong/HKU-691/2021 (HKU691) (GISAID accession
106 number EPI_ISL_7138045) and hCoV-19/Hong Kong/HKU-344/2021 (HKU344-R346K)
107 (GISAID accession number EPI_ISL_7357684) were isolated from the combined
108 nasopharyngeal-throat swabs of two COVID-19 patients in Hong Kong. Serum specimens from
109 recipients of BNT162b2 or Coronavac vaccines were collected in a vaccine trial conducted at
110 two vaccination centers in Hong Kong [12]. This study was approved by the the Institutional
111 Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster
112 (UW 13-265; UW-21-214), and the Kowloon West Cluster REC (KW/EX-20-038[144-26]).

113

114 **Viral culture**

115 Viral culture was performed in a biosafety level 3 facility as we described previously [6].
116 Briefly, TMPRSS2-expressing VeroE6 (VeroE6/TMPRSS2) cells (JCRB Cat#JCRB1819) were

117 seeded with 100 μ L of minimum essential medium (MEM) (Thermo Fisher Scientific) at 4×10^4
118 cells/mL in 96-well plate and incubated at 37°C in a carbon dioxide incubator until confluence
119 for inoculation. Each well was inoculated with 30 μ L of clinical specimen. Virus-induced
120 cytopathic effect was examined. Cultures with more than 50% virus-induced cytopathic effect
121 was expanded to large volume and 50% tissue culture infective dose (TCID₅₀) was determined.

122 The whole genome sequence of the culture isolates was determined using nanopore
123 sequencing (Oxford Nanopore Technologies). Purified libraries were sequenced with the Oxford
124 Nanopore MinION device using R9.4.1 flow cells. We described the lineage information using
125 the Pangolin nomenclatures [13].

126

127 **Live virus microneutralization (MN) assay**

128 Live virus MN assay was performed as we described previously [6]. Briefly, serum
129 specimens were serially diluted in 2-folds from 1:10. Duplicates of each serum was mixed with
130 100 TCID₅₀ of a lineage A virus (GISAID accession number: EPI_ISL_434571), a B.1.351
131 (Beta variant) (GISAID accession number: EPI_ISL_2423556), B.1.617.2 (delta variant)
132 (GISAID accession number: EPI_ISL_3221329) virus isolates for 1 hour, and the serum-virus
133 mixture was then added to VeroE6/TMPRSS2 cells. After incubation for 3 days, cytopathic
134 effect was examined.

135

136 **Statistical analysis**

137 Statistical analysis was performed using SPSS 26.0 (IBM SPSS Statistics) and GraphPad
138 PRISM 9.1.1 (GraphPad Software, San Diego CA, USA). Log-transformed microneutralization
139 antibody titers against different variants were compared using one-way ANOVA with Dunn's

140 multiple comparisons test. For the purpose of statistical analysis, an MN titer of <10 was
141 considered as 5. A P value of <0.05 was considered statistically significant.

142

143 **RESULTS**

144 This study included serum specimens from a total of 50 adult vaccine recipients, among
145 which 25 received BNT162b2 and 25 received the Coronavac. The median age was 48 years,
146 with an interquartile range of 40 to 54 years (Table 1). There was no statistical significant
147 difference in the age or sex between the BNT162b2 and Coronavac groups. All individuals have
148 received two doses of COVID-19 vaccines, and the serum specimens were collected 56 days
149 after the first dose of vaccine.

150 We included 2 Omicron variant culture isolates (HKU691 and HKU344-R346K) in this
151 study. Both isolates belong to the Pangolin BA.1 lineage. These two virus isolates differ by only
152 2 nucleotides (Table 2). HKU-344-R346K has a non-synonymous mutation G22599A, which
153 results in R346K mutation in the spike protein. Spike R346K mutation is present in 8.5%
154 (131/1546) of the Omicron variant sequences deposited into GISAID database as of 10th
155 December 2021 (Supplementary Table S1).

156 Among BNT162b2 recipients, the seropositive rate of the Omicron variants HKU691 and
157 HKU344-R346K was only 20 and 24%, respectively, while the seropositive rates were 100% for
158 beta variant, delta variant and ancestral virus. The geometric mean MN titer (GMT) against
159 HKU691 (5.43) and HKU344-R346K (6.42) was 39.9 and 35.7-fold lower than those of the
160 ancestral lineage A virus (229.4), respectively (P <0.0001) (Figure 1; Table 3). The GMT against
161 both omicron variants were also significantly lower than those against the beta variant (25.7;
162 P=0.0057 for HKU691 and P=0.0175 for HKU344-R346K) or the delta variant (124.7;

163 P<0.0001). Among Coronavac recipients, none were seropositive for both Omicron variant
164 isolates or the beta variant, while only 68% was seropositive for delta variant.

165

166 **DISCUSSIONS**

167 The Omicron variant poses a potential threat to vaccine effectiveness because of the
168 presence of numerous mutations at the spike protein that have been shown to affect binding of
169 neutralizing antibodies. In this study, we demonstrated that both Omicron variants have reduced
170 susceptibility to neutralization by sera collected from COVID-19 vaccine recipients. None of the
171 Coronavac recipients had detectable neutralizing antibody to the Omicron variants. The
172 susceptibility was similar for the omicron variants with or without the spike R346K mutation.

173 Our results corroborate with the results from recent preprint articles. Cele et al showed
174 that the neutralization titer is 41-fold lower than that of a D614G virus [14]. In another study,
175 Cao et al used pseudovirus neutralization assay and yeast-display RBD library to demonstrate
176 that the Omicron variant is shown to escape from neutralizing monoclonal antibodies [15]. Our
177 study is unique in 2 different ways. First, we tested serum from Coronavac recipients. This is
178 especially important because Coronavac is widely used globally. Second, we included an
179 Omicron variant with R346K mutation. The R346K mutation is a particular concern because the
180 spike R346K mutation is located within the RBD. R346K mutation is also present in the Mu
181 variant, which has been shown to have to be least susceptible to sera from COVID-19 vaccine
182 recipients [16]. The spike amino acid residue 346 is located in the epitope of a class 3
183 monoclonal neutralizing antibody C135 [17], and escape mutants during C135 passage contains
184 the R346K mutation [18].

185 Neutralizing antibody titer correlated with vaccine protection in clinical trials and in
186 animal studies [19,20]. Previous studies showed that the Beta (B.1.351) and Mu (B.1.621)
187 variants are least susceptible to sera from COVID-19 vaccine recipients [5,16]. Our study
188 showed that neutralizing antibodies generated by BNT162b2 and Coronavac vaccines are much
189 less effective in neutralizing the Omicron variant than the Beta variant. Therefore, Omicron may
190 be associated with a higher risk of breakthrough infection for COVID-19 vaccine recipients, or
191 reinfection among recovered COVID-19 recipients. Indeed, preliminary data from South Africa
192 suggest that the emergence of Omicron variant is associated with a higher risk of reinfection [9].
193 The Omicron variant carries important spike mutations that are present in both Beta (K417N,
194 N501Y) and Delta (T478K) variants. The Omicron variant also contains the E484A mutation,
195 which is located within the epitope recognized by clinically approved monoclonal antibodies
196 bamlanivimab and casirivimab [21,22], and E484A has been shown to escape neutralization by
197 antibody [23]. Our previous study showed that RBDs carrying E484K have lowest binding with
198 antibodies in serum from vaccinees or from natural COVID-19 patients [5]. Furthermore,
199 Omicron variant also carries G446S and Q493R. Mutations at spike amino acid residue 446 and
200 493 have been shown to affect the binding of monoclonal antibodies or from convalescent donor
201 polyclonal serum IgG [24,25]. The effect of other mutations are less well-defined. It remains to
202 be determined which are the critical amino acid residues that confer reduced susceptibility.

203 COVID-19 vaccines can also induce neutralizing antibodies that target the spike protein
204 NTD and S2 region [26]. The Omicron variant contains several mutations in these regions. Our
205 previous studies show that mutations in these domains can affect the neutralizing activities [6].
206 Whether these novel mutations affect the neutralizing activity remains to be determined.

207 There are several limitations in this study. First, we assessed serum specimens that were
208 collected 56 days after the first dose of vaccine. Since antibody waning is well reported [27], it is
209 likely that the neutralization antibody titer and seropositive rate would be lower for serum
210 collected longer after the vaccination. Second, this study only included adult vaccine recipients.
211 Since the antibody titer can be higher among adolescents and children, studies in the pediatric
212 age group would be required. Third, we have not assessed the T cell immunity against the
213 Omicron variant, which correlates with disease severity. Fourth, since all Coronavac recipients
214 had an MN titer of <10 against the Omicron variant and the GMT against the ancestral virus is
215 only 21.73, an accurate fold-reduction in neutralizing antibody titer cannot be determined.

216 In conclusion, the reduced susceptibility of Omicron variant to vaccine-induced
217 neutralizing antibody, together with the rapid spread of this variant, suggests that newer
218 generation vaccines should be designed to cover this variant. However, before the availability of
219 these next generation vaccines, booster doses of currently available vaccines will likely render
220 most people having protective levels of neutralizing antibody titers.

221

222 **ACKNOWLEDGEMENT**

223 We gratefully acknowledge the originating and submitting laboratories who contributed
224 sequences to GISAID (Supplementary Table S1). This study was partly supported by the Health
225 and Medical Research Fund, the Food and Health Bureau, The Government of the Hong Kong
226 Special Administrative Region (HKSAR) (Ref no.: COVID1903010, Project 1), Consultancy
227 Service for Enhancing Laboratory Surveillance of Emerging Infectious Diseases and Research
228 Capability on Antimicrobial Resistance for Department of Health of the HKSAR; and donations
229 of Richard Yu and Carol Yu, Shaw Foundation Hong Kong, Michael Seak-Kan Tong, May Tam

230 Mak Mei Yin, Lee Wan Keung Charity Foundation Limited, the Providence Foundation Limited
231 (in memory of the late Lui Hac Mih), Hong Kong Sanatorium & Hospital, Respiratory Viral
232 Research Foundation Limited, Hui Ming, Hui Hoy and Chow Sin Lan Charity Fund Limited,
233 Chan Yin Chuen Memorial Charitable Foundation, Marina Man-Wai Lee, the Hong Kong
234 Hainan Commercial Association South China Microbiology Research Fund, the Jessie & George
235 Ho Charitable Foundation, Kai Chong Tong, Tse Kam Ming Laurence, Foo Oi Foundation
236 Limited, Betty Hing-Chu Lee, and Ping Cham So. The funding sources had no role in the study
237 design, data collection, analysis, interpretation, or writing of the report.

238

239 **CONFLICT OF INTEREST**

240 HC, KY Y and KKWT report collaboration with Sinovac and Sinopharm. Other authors
241 declare no conflict of interest.

242

243 **REFERENCES**

- 244 [1] Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia
245 associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of
246 a family cluster. *Lancet* 2020;395:514-23
- 247 [2] Cheng VC, Fung KS, Siu GK, Wong SC, Cheng LS, Wong MS, et al. Nosocomial
248 Outbreak of Coronavirus Disease 2019 by Possible Airborne Transmission Leading to a
249 Superspreading Event. *Clin Infect Dis* 2021;73:e1356-e64
- 250 [3] To KK, Sridhar S, Chiu KH, Hung DL, Li X, Hung IF, et al. Lessons learned one year
251 after SARS-CoV-2 emergence leading to COVID-19 pandemic. *Emerg Microbes Infect*
252 2021;10.1080/22221751.2021.1898291:1-89
- 253 [4] The World Health Organization. COVID-19 vaccine tracker. Available at
254 <https://covid19.trackvaccines.org/agency/who/>. Accessed on 3rd December 2021
- 255 [5] Chen LL, Lu L, Choi CY, Cai JP, Tsoi HW, Chu AW, et al. Impact of SARS-CoV-2
256 variant-associated RBD mutations on the susceptibility to serum antibodies elicited by COVID-
257 19 infection or vaccination. *Clin Infect Dis* 2021;10.1093/cid/ciab656
- 258 [6] Lu L, Chu AW, Zhang RR, Chan WM, Ip JD, Tsoi HW, et al. The impact of spike
259 N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum.
260 *EBioMedicine* 2021;71:103544
- 261 [7] Cevik M, Grubaugh ND, Iwasaki A, Openshaw P. COVID-19 vaccines: Keeping pace
262 with SARS-CoV-2 variants. *Cell* 2021;184:5077-81
- 263 [8] Wong SC, Au AK, Chen H, Yuen LL, Li X, Lung DC, et al. Transmission of Omicron
264 (B.1.1.529) - SARS-CoV-2 Variant of Concern in a designated quarantine hotel for travelers: a

- 265 challenge of elimination strategy of COVID-19. Accepted and In Press. Lancet Reg Health West
266 Pac 2021
- 267 [9] Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, et
268 al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant
269 in South Africa. medRxiv 2021;10.1101/2021.11.11.21266068:2021.11.11.21266068
- 270 [10] Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19
271 pandemic. Lancet 2021;10.1016/S0140-6736(21)02758-6
- 272 [11] Agency UHS. SARS-CoV-2 variants of concern and variants under investigation in
273 England. Technical Briefing 31. Available at
274 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1040076/Technical_Briefing_31.pdf)
275 [/1040076/Technical_Briefing_31.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1040076/Technical_Briefing_31.pdf). Accessed on 13th December 2021. 2021
- 276 [12] Zhang R, Khong KW, Leung KY, Liu D, Fan Y, Lu L, et al. Antibody response of
277 BNT162b2 and CoronaVac platforms in COVID-19 recovered individuals against SARS-CoV-2
278 wild type and delta variant. Accepted and In Press. Vaccines 2021
- 279 [13] Rambaut A, Holmes EC, O'Toole A, Hill V, McCrone JT, Ruis C, et al. A dynamic
280 nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol
281 2020;10.1038/s41564-020-0770-5
- 282 [14] Cele S, Jackson L, Khan K, Khoury D, Moyo-Gwete T, Tegally H, et al. SARS-CoV-2
283 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and
284 requires ACE2 for infection. Available at [https://www.ahri.org/wp-](https://www.ahri.org/wp-content/uploads/2021/12/MEDRXIV-2021-267417v1-Sigal.pdf)
285 [content/uploads/2021/12/MEDRXIV-2021-267417v1-Sigal.pdf](https://www.ahri.org/wp-content/uploads/2021/12/MEDRXIV-2021-267417v1-Sigal.pdf). Accessed on 8th December
286 2021.

- 287 [15] Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, et al. B.1.1.529 escapes the
288 majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes. *bioRxiv*
289 2021;10.1101/2021.12.07.470392:2021.12.07.470392
- 290 [16] Uriu K, Kimura I, Shirakawa K, Takaori-Kondo A, Nakada TA, Kaneda A, et al.
291 Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum. *N Engl J*
292 *Med* 2021;10.1056/NEJMc2114706
- 293 [17] Barnes CO, Jette CA, Abernathy ME, Dam KA, Esswein SR, Gristick HB, et al. SARS-
294 CoV-2 neutralizing antibody structures inform therapeutic strategies. *Nature* 2020;588:682-7
- 295 [18] Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, et al. Escape from
296 neutralizing antibodies by SARS-CoV-2 spike protein variants. *Elife* 2020;9
- 297 [19] Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al.
298 Neutralizing antibody levels are highly predictive of immune protection from symptomatic
299 SARS-CoV-2 infection. *Nat Med* 2021;27:1205-11
- 300 [20] Corbett KS, Nason MC, Flach B, Gagne M, O'Connell S, Johnston TS, et al. Immune
301 correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates.
302 *Science* 2021;373:eabj0299
- 303 [21] Starr TN, Greaney AJ, Dingens AS, Bloom JD. Complete map of SARS-CoV-2 RBD
304 mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016.
305 *Cell Rep Med* 2021;2:100255
- 306 [22] Hansen J, Baum A, Pascal KE, Russo V, Giordano S, Wloga E, et al. Studies in
307 humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. *Science*
308 2020;369:1010-4

- 309 [23] Liu Z, VanBlargan LA, Bloyet LM, Rothlauf PW, Chen RE, Stumpf S, et al.
310 Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody
311 neutralization. *Cell Host Microbe* 2021;29:477-88 e4
- 312 [24] Clark SA, Clark LE, Pan J, Coscia A, McKay LGA, Shankar S, et al. SARS-CoV-2
313 evolution in an immunocompromised host reveals shared neutralization escape mechanisms. *Cell*
314 2021;184:2605-17 e18
- 315 [25] Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY, et al.
316 Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect
317 recognition by polyclonal human plasma antibodies. *Cell Host Microbe* 2021;29:463-76 e6
- 318 [26] Amanat F, Thapa M, Lei T, Ahmed SMS, Adelsberg DC, Carreno JM, et al. SARS-CoV-
319 2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. *Cell*
320 2021;184:3936-48 e10
- 321 [27] Thomas SJ, Moreira ED, Jr., Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety
322 and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. *N Engl J Med*
323 2021;385:1761-73
- 324
- 325

326 **FIGURE LEGEND**

327 **Figure 1.** Comparison of microneutralization antibody titers between the Omicron variant and
328 other variants or ancestral SARS-CoV-2 virus. All serum specimens were collected 56 days after
329 the first dose of vaccine. A) Sera from all vaccine recipients. B) Sera from BNT162b2 mRNA
330 vaccine recipients. C) Sera from Coronavac vaccine recipients.

331 * P < .05; ** P < .01; *** P < .001; **** P < .0001.

332

333

334 **Table 1.** Demographics of vaccine recipients

	All vaccinees (n=50)	BNT162b2 (n=25)	CoronaVac (n=25)	P value
Female sex	31 (62)	14 (56)	17 (68)	0.561 ^a
Median age in years (range)	48 (23-61)	47 (23-61)	52 (23-60)	0.183 ^b

335 Data expressed as no. (%)

336 ^a By Fisher's exact test

337 ^b By Mann-Whitney U test

338

339

340 **Table 2.** Difference in nucleotide and amino acid mutations between the two Omicron variant strains used
341 in this study

Gene	Nucleotide				Amino acid mutation			
	Position ^a	WH1	HKU691	HKU344-R346K	Position	WH1	HKU691	HKU344-R346K
NSP2	2470	C	C	T	555	A	A	A
Spike	22599	G	G	A	346	R	R	K

342 Abbreviations: HKU691, Omicron variant hCoV-19/Hong Kong/HKU-691/2021; HKU344-R346K, Omicron
343 variant hCoV-19/Hong Kong/HKU-344/2021; WH1; SARS-CoV-2 isolate Wuhan-Hu-1 (NCBI accession number:
344 MN908947)

345 ^a The nucleotide position is numbered according the reference genome Wuhan-Hu-1 (Genbank accession number
346 MN908947.3)

347

348


349 **Table 3.** Difference in GMT between Omicron variant and other earlier viruses

	Lineage A (Ancestral virus)	Beta variant	Delta variant	Omicron variant HKU691	Omicron variant HKU344- R346K
Seropositive rate^a % (no. positive/total)					
All	100 (50/50)	50 (25/50)	84 (42/50)	10 (5/50)	12 (6/50)
BNT162b2	100 (25/25)	100 (25/25)	100 (25/25)	20 (5/25)	24 (6/25)
CoronaVac	100 (25/25)	0 (0/25)	68 (17/25)	0 (0/25)	0 (0/25)
Geometric mean titer (95% CI)					
All	70.6 (48.3-103.2)	11.3 (2.6-11.3)	35.8 (4.0-35.8)	5.36 (5.05-5.69)	5.66 (5.07-6.33)
BNT162b2	229.4 (176.4-298.4)	25.7 (19.6-33.7)	124.7 (100.4-154.8)	5.43 (5.11-6.46)	6.42 (5.17-7.97)
CoronaVac	21.7 (17.1-27.6)	5 (5-5)	10.3 (7.9-13.4)	5 (5-5)	5 (5-5)
Fold decrease of GMT when compared with Lineage A					
All	N/A	6.2	2.0	13.2	12.5
BNT162b2	N/A	8.9	1.8	39.9	35.7
CoronaVac	N/A	4.4	2.1	4.3	4.3


350 ^a MN titer ≥ 10

351

All vaccinees



BNT162b2



Coronavac

